Small pharmacies gain permission to prepare popular unapproved wellness peptides

Policy Change

Small compounding pharmacies can soon prepare six wellness peptides without facing federal penalties, despite a lack of formal clearance from drug regulators. The Department of Health and Human Services announced it will not take action against small facilities that make these specific substances. Health Secretary Robert F. Kennedy Jr. backed wider access to these compounds and stated he takes some of them personally.

Production Limits

While the shift offers a safer choice than online gray-market items bought from overseas vendors, strict limits will remain in place. The rule only applies to small 503A compounding pharmacies and excludes larger 503B facilities that make products in bulk. Joshua Fritzler, who leads an enterprise named Olympia and Wesley Pharmaceuticals in Florida, noted that small producers cannot keep pace with high public interest. Drug safety advocates strongly criticized the move, warning it bypasses standard agency safety reviews and puts consumers in danger.

Context

Compounding pharmacies custom-mix medications to meet specific patient needs when commercially manufactured drugs are not suitable. These facilities operate under different rules than large drug manufacturers that produce standardized pharmaceuticals on a massive scale. The Food and Drug Administration normally requires extensive clinical trials to prove a drug is safe and effective before it goes on sale.